Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.49 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.48 |
| ▸ | PRKCB | P05771 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | PRKCH | P24723 | 1/20 | 0.47 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.47 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | CTSV | O60911 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.44 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15797114 | 0.89 | PRKCB (0.54) | GSK3BPTGS2CAMK2DPRKCBPRKCA | |
| SCHEMBL5686050 | 0.87 | CAMK2D (0.57) | GSK3BCAMK2DPRKCBPRKCAPRKCH | |
| SCHEMBL22592333 | 0.84 | PDE9A (0.51) | GSK3BPTGS2CAMK2DPRKCBPRKCA | |
| SCHEMBL19217027 | 0.84 | IMPDH2 (0.67) | CAMK2DPRKCBPRKCAPRKCHPRKCE | |
| SCHEMBL15797125 | 0.83 | CAMK2D (0.46) | GSK3BPTGS2CAMK2DPRKCBPRKCA | |
| SCHEMBL19216937 | 0.83 | PRKCB (0.47) | GSK3BPTGS2CAMK2DPRKCBPRKCA | |
| SCHEMBL17210884 | 0.83 | GSK3B (0.50) | GSK3BPTGS2MAPK14CTSVCTSL | |
| SCHEMBL15797297 | 0.83 | GSK3B (0.64) | GSK3BPTGS2CAMK2DMAPK14CTSV | |
| SCHEMBL15797184 | 0.82 | PDE9A (0.49) | GSK3BCAMK2DPRKCBPRKCAPRKCH | |
| SCHEMBL15798951 | 0.81 | GSK3B (0.52) | GSK3BPTGS2CAMK2DPRKCBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928465-B1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING CANCER | CENTOGENE GMBH (DE) | 2020-11-18 | — | — | EP | disclosed |
| US-10420754-B2 | Use of maleimide derivatives for preventing and treating cancer | CENTOGENE AG (DE) | 2019-09-24 | — | — | US | disclosed |
| US-9993463-B2 | Use of maleimide derivatives for preventing and treating cancer | CENTOGENE AG (DE) | 2018-06-12 | — | — | US | disclosed |
| US-9724331-B2 | Use of maleimide derivatives for preventing and treating leukemia | CENTOGENE AG (DE) | 2017-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10420754-B2 | Use of maleimide derivatives for preventing and treating cancer | MGMT, IDH3A, CYP3A43 | GSK3B 2325/4885PTGS2 2481/4885CAMK2D 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.